Quest Diagnostics Price to Free Cash Flow Ratio 2010-2024 | DGX

Quest Diagnostics current price to free cash flow ratio as of February 02, 2025 is 17.95.

  • Quest Diagnostics average price to free cash flow ratio for 2024 was 16.67, a 13.36% increase from 2023.
  • Quest Diagnostics average price to free cash flow ratio for 2023 was 19.24, a 77.33% decline from 2022.
  • Quest Diagnostics average price to free cash flow ratio for 2022 was 10.85, a 20.96% increase from 2021.

Price to free cash flow ratio can be defined as

Quest Diagnostics Price to Free Cash Flow Ratio 2010-2024 | DGX

  • Quest Diagnostics average price to free cash flow ratio for 2024 was 16.67, a 13.36% increase from 2023.
  • Quest Diagnostics average price to free cash flow ratio for 2023 was 19.24, a 77.33% decline from 2022.
  • Quest Diagnostics average price to free cash flow ratio for 2022 was 10.85, a 20.96% increase from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.7B
DaVita (DVA)$14.2B
Encompass Health (EHC)$9.6B
Chemed (CHE)$8.4B
Elanco Animal Health (ELAN)$6.1B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$5B
LifeStance Health (LFST)$3.1B
Amedisys (AMED)$3B
Addus HomeCare (ADUS)$2.3B
Astrana Health (ASTH)$2.1B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$945M
Aveanna Healthcare Holdings (AVAH)$945M
Atai Life Sciences (ATAI)$252M
Bioqual (BIOQ)$55M
Daxor (DXR)$38M
Ontrak (OTRK)$7M
MEDIROM Healthcare Technologies (MRM)$4M
IMAC Holdings (BACK)$2M
Psychemedics (PMD)$0M